ArticleJournal for immunotherapy of cancer2025

Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers.

Claire Morgan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.